ATE433998T1 - Divalent anti-t-zellen immuntoxinen und deren verwendung - Google Patents

Divalent anti-t-zellen immuntoxinen und deren verwendung

Info

Publication number
ATE433998T1
ATE433998T1 AT98911483T AT98911483T ATE433998T1 AT E433998 T1 ATE433998 T1 AT E433998T1 AT 98911483 T AT98911483 T AT 98911483T AT 98911483 T AT98911483 T AT 98911483T AT E433998 T1 ATE433998 T1 AT E433998T1
Authority
AT
Austria
Prior art keywords
recipient
cell
donor
immunotoxin
cells
Prior art date
Application number
AT98911483T
Other languages
English (en)
Inventor
David Neville
Joshua Scharff
Stuart Knechtle
Judith Thomas
Jerry Thompson
Huaizhong Hu
Shenglin Ma
Original Assignee
Us Health
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Uab Research Foundation filed Critical Us Health
Application granted granted Critical
Publication of ATE433998T1 publication Critical patent/ATE433998T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT98911483T 1997-03-05 1998-03-05 Divalent anti-t-zellen immuntoxinen und deren verwendung ATE433998T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3998797P 1997-03-05 1997-03-05
PCT/US1998/004303 WO1998039363A2 (en) 1997-03-05 1998-03-05 Immunotoxins and methods of inducing immune tolerance

Publications (1)

Publication Number Publication Date
ATE433998T1 true ATE433998T1 (de) 2009-07-15

Family

ID=21908461

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98911483T ATE433998T1 (de) 1997-03-05 1998-03-05 Divalent anti-t-zellen immuntoxinen und deren verwendung

Country Status (8)

Country Link
US (2) US6632928B1 (de)
EP (1) EP1015496B1 (de)
JP (1) JP2002501484A (de)
AT (1) ATE433998T1 (de)
AU (1) AU733898B2 (de)
CA (1) CA2284079C (de)
DE (1) DE69840913D1 (de)
WO (1) WO1998039363A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288254B2 (en) 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US6632928B1 (en) 1997-03-05 2003-10-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxins and methods of inducing immune tolerance
US7517527B2 (en) 1995-10-30 2009-04-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
US7125553B1 (en) 1996-04-15 2006-10-24 The United States of America as represented by the Department of Health and Human Services c/o Centers for Disease Control and Prevention Methods of inducing immune tolerance using immunotoxins
WO2000040270A2 (en) * 1999-01-08 2000-07-13 Wisconsin Alumni Research Foundation Methods of prolonging transplant survival using immunotoxins and costimulation blockade of cd154 and cd28
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
HK1042648A1 (zh) * 1999-04-14 2002-08-23 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, C/O National Institutes Of Health, Office Of Technology Transfer 用於诱导对移植物的免疫耐受的含有免疫毒素和抑制树突细胞成熟的试剂的组合物
WO2000078348A1 (en) * 1999-06-17 2000-12-28 University Of Vermont And State Agricultural College Autologous adoptive immunotherapy with primed antigen-specific t cells or b cells
US6492498B1 (en) 1999-11-15 2002-12-10 Regents Of The University Of Minnesota Multimeric immunotoxins
CA2409746C (en) * 2000-05-18 2014-11-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
EP2348045A1 (de) * 2001-07-24 2011-07-27 Debiovision Inc. Rezeptor, dessen Verwendung sowie Mausantikörper
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US7105347B2 (en) 2002-07-30 2006-09-12 Corning Incorporated Method and device for protein delivery into cells
US7691580B2 (en) * 2003-01-29 2010-04-06 Corning Incorporated Reverse protein delivery into cells on coded microparticles
US20090029460A1 (en) * 2004-01-26 2009-01-29 Peter Vollmers Neoplasm-specific polypeptides and their uses
WO2008020827A2 (en) * 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
WO2007050405A2 (en) * 2005-10-21 2007-05-03 Medical College Of Georgia Research Institute, Inc. The induction of indoleamine 2,3-dioxygenase in dendritic cells by tlr ligands and uses thereof
AR063384A1 (es) 2006-10-25 2009-01-28 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
EP2738257A1 (de) 2007-05-22 2014-06-04 Amgen Inc. Zusammensetzungen und Verfahren zur Herstellung bioaktiver Fusionsproteine
EP2197903B9 (de) * 2007-09-04 2015-04-22 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Deletionen in der domäne ii von pseudomonas-exotoxin, die die nichtspezifische toxizität vermindern
PE20120630A1 (es) * 2009-08-17 2012-05-26 Roche Glycart Ag Inmunoconjugados dirigidos
EP2565667A1 (de) 2011-08-31 2013-03-06 Friedrich-Alexander-Universität Erlangen-Nürnberg Ankunftsrichtungsschätzung mittels mit einem Wasserzeichen versehenen Audiosignalen und Mikrofonanordnungen
WO2025050404A1 (zh) * 2023-09-08 2025-03-13 成都维瑾柏鳌生物医药科技有限公司 一种药物组合物及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520226A (en) 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
AU6733287A (en) 1985-11-13 1987-06-02 Murphy, J.R. Cys codon-modified dna
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
JPH03503887A (ja) 1988-02-03 1991-08-29 エクソウマ　コーポレーション 自己免疫疾患に対する抗ｔ細胞イムノトキシンの治療的使用
IL89504A0 (en) 1988-03-08 1989-09-10 Univ Wyoming Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same
US5980896A (en) * 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
CA2076753A1 (en) 1990-02-26 1991-08-27 Anthony J. Radford Shuttle plasmid for escherichia coli and mycobacteria
US5725857A (en) 1991-02-11 1998-03-10 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
US5167956A (en) 1991-02-11 1992-12-01 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in-vivo t cell suppressant activity
WO1993015113A1 (en) 1992-01-24 1993-08-05 Tanox Biosystems, Inc. An immunotoxin including a cytotoxin with an unpaired cysteine residue in or near its receptor-binding site
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US5688781A (en) 1994-08-19 1997-11-18 Bristol-Myers Squibb Company Method for treating vascular leak syndrome
AU5663796A (en) 1995-04-14 1996-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of inducing immune tolerance using immunotoxins
US6632928B1 (en) 1997-03-05 2003-10-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxins and methods of inducing immune tolerance
US6103235A (en) 1995-10-30 2000-08-15 The United States Of America As Represented By The Department Of Health And Human Services Methods of inducing immune tolerance using immunotoxins
US5747474A (en) * 1996-07-29 1998-05-05 Immune Modulation, Inc. Immunosuppression by administration of N6,N6 -disubstituted cAMP's, analogues thereof, and related nucleosides
CA2283497A1 (en) 1997-03-05 1998-09-11 David M. Neville Vectors and methods for expression of mutant proteins
US5801193A (en) * 1997-04-15 1998-09-01 Immune Modulation, Inc. Compositions and methods for immunosuppressing
CA2326692C (en) 1998-04-22 2012-11-13 David M. Neville Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
WO2000040270A2 (en) 1999-01-08 2000-07-13 Wisconsin Alumni Research Foundation Methods of prolonging transplant survival using immunotoxins and costimulation blockade of cd154 and cd28
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
HK1042648A1 (zh) 1999-04-14 2002-08-23 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, C/O National Institutes Of Health, Office Of Technology Transfer 用於诱导对移植物的免疫耐受的含有免疫毒素和抑制树突细胞成熟的试剂的组合物

Also Published As

Publication number Publication date
WO1998039363A3 (en) 1999-04-01
AU6542698A (en) 1998-09-22
CA2284079C (en) 2009-05-12
WO1998039363A2 (en) 1998-09-11
US20030185825A1 (en) 2003-10-02
EP1015496B1 (de) 2009-06-17
EP1015496A2 (de) 2000-07-05
US6632928B1 (en) 2003-10-14
CA2284079A1 (en) 1998-09-11
AU733898B2 (en) 2001-05-31
JP2002501484A (ja) 2002-01-15
DE69840913D1 (de) 2009-07-30

Similar Documents

Publication Publication Date Title
DE69840913D1 (de) Divalent anti-t-zellen immuntoxinen und deren verwendung
DE69433013D1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
EP1245676A4 (de) Humane monoklonale antikörper gegen den tgf-beta ii rezeptor und dessen medizinische verwendung
ATE237339T1 (de) Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen
MD1444B2 (ro) Metode de inducere a toleranţei celulelor T faţă de un transplant de organe sau ţesuturi
NO901986D0 (no) Nytt antistoff-leveringssystem for biologisk respons-modifiserende midler.
EP0681475A4 (de) Therapeutische inhibitoren der zellen der glatten gefässmuskulatur
ATE245030T1 (de) Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen
RU98100114A (ru) Использование нейро-производных эмбриональных клеточных линий для трансплантационной терапии
EP0859625A4 (de) Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
EP0313378A3 (de) Methoden und Zusammensetzungen für vorübergehende Elimination von humoralen immunen Antikörpern
WO1992013562A1 (en) An immunotoxin with in vivo t cell suppressant activity
WO1996032137A3 (en) Methods of inducing immune tolerance using immunotoxins
EP1003552A4 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGENE ZUR HEMMUNG VON T-ZELL AKTIVIERUNG UND WACHSTUM
DE69434244D1 (de) Verbesserte krebstherapie
WO1996032137B1 (en) Methods of inducing immune tolerance using immunotoxins
Trainin et al. Some characteristics of a thymic humoral factor determined by assay in vivo of DNA synthesis in lymph nodes of thymectomized mice
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
ATE297702T1 (de) Induktion von immunologischer toleranz
DE69434220T2 (de) Verfahren zur verhütung der nebenwirkungen und unempfindlichkeit gegenüber therapeutischen verwendungen von toxinen
US5378815A (en) Process for indirect targeted immunocytolysis
Natali et al. Immune complex formation in NZBW mice after ultraviolet radiation
ATE432080T1 (de) Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation
Wiley et al. The in-vitro inhibition of rat alloantigen presentation by immunotoxins--implications for allografting
Wiley et al. An a-chain ricin immunotoxin targeted against rat class II major histocompatibility complex molecules: in vitro and in vivo effects

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties